A Novel Pseudogene Methylation Signature to Predict Temozolomide Outcome in Non-G-CIMP Glioblastomas

Figure 2

The performance of the pseudogene methylation signature for TMZ response. Survival comparison of patients treated with RT/TMZ vs. RT alone in (a) low-risk groups and (b) high-risk groups; and (c) forest plots of comparison in OS; RT/TMZ vs. RT monotherapy in patients with either low-risk or high-risk tumors.

(a)

(b)

(c)